Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Pyrotinib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Pyrotinib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Pyrotinib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Pyrotinib
Generic Name (API): Pyrotinib maleate
Dosage Form & Strength: 80 mg, 160 mg
Route: Oral
Drug Class: Irreversible pan-HER (EGFR/HER2/HER4) tyrosine kinase inhibitor

Manufacturer / Innovator:

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Pyrotinib Used For?

Pyrotinib is a once-daily targeted tablet for HER2-positive breast cancer. It was discovered and is made in China by Jiangsu Hengrui Pharmaceuticals, and it is sold there under the brand name 艾瑞妮® (Irene®).

Its first Chinese licence, for use with capecitabine, came as a conditional NMPA approval in August 2018 and became a full approval in July 2020. Two more breast cancer uses have been added since, so the approved list in China now reads:

  • Recurrent or metastatic HER2-positive breast cancer in patients who have already had HER2 antibody treatment, taken together with capecitabine tablets
  • First-line treatment of advanced HER2-positive breast cancer, added to standard HER2 antibody therapy plus taxane chemotherapy (approved April 2023)
  • Treatment before surgery (neoadjuvant) for HER2-positive early or locally advanced breast cancer, again alongside standard HER2 antibody therapy and taxane chemotherapy (conditionally approved June 2022)

This is a prescription cancer medicine and should only be started and monitored by a medical oncologist.

How It Works

In HER2-positive breast cancer, the cancer cells carry too many HER2 receptors, which keep sending "grow and divide" signals. This medicine is a small molecule that slips inside the cell and binds permanently (irreversibly) to the switch area of three related receptors: HER1 (EGFR), HER2 and HER4. Because it acts from inside the cell, it can still block the signal when antibody treatments given as drips have stopped working well.

What the Trials Showed

The approval with capecitabine rests on the phase 3 PHOEBE study (The Lancet Oncology, 2021). It enrolled 267 women whose metastatic breast cancer had been treated before with a HER2 antibody and a taxane. With the capecitabine combination, the cancer was held in check for a median of 12.5 months, against 6.8 months with a comparison medicine plus capecitabine.

In the first-line PHILA trial (BMJ, 2023; 590 patients), adding it to standard HER2 treatment lengthened median progression-free survival from 10.4 to 24.3 months. Before surgery, the PHEDRA trial (BMC Medicine, 2022; 355 patients) found no remaining invasive cancer in the breast and lymph nodes in 41.0% of people, compared with 22.0% on placebo.

Recommended Dosage

In the trials, the usual dose was:

  • 400 mg by mouth once a day, taken every day without a break
  • With capecitabine: 1000 mg/m² twice a day on days 1 to 14 of every 21-day cycle
  • If side effects are hard to manage, the dose can be stepped down to 320 mg and then 240 mg a day

The tablets come in 80 mg and 160 mg strengths, so the daily dose is made up from a mix of the two. Follow the exact plan your oncologist and the Chinese pack leaflet give you.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Diarrhoea: this is the side effect that matters most. Severe (grade 3 or worse) diarrhoea affected 31% of patients in PHOEBE, 44.4% in PHEDRA and 46% in PHILA. It tends to be worst in the first three-week cycle and usually eases after that. Keep anti-diarrhoea tablets at home as your doctor advises, drink plenty of fluids, and call the team if loose stools do not settle within a day.

  • Hand-foot syndrome: sore, red or peeling palms and soles were seen at a severe level in 16% of people taking it with capecitabine, similar to the comparison group (15%).
  • Low blood counts: when combined with taxane chemotherapy, severe drops in neutrophils were very common (63% in PHILA), although the rate was almost the same with placebo (65%). Blood tests are done before each cycle.
  • Potassium and anaemia: low potassium (14%) and anaemia (9%) at a severe level were more frequent than with placebo in PHILA, often linked to fluid lost through diarrhoea.
  • Dose changes: about a quarter of patients in PHILA (26%) needed a dose reduction because of side effects, and 13% stopped at least one of the medicines.

Other points: serious side effects were reported in 10% of PHOEBE patients. Tell your doctor about every other medicine and supplement you take, and use reliable contraception, because safety in pregnancy and breastfeeding has not been established.

How to Access Pyrotinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Pyrotinib to India?

A named-patient import is allowed only in the patient's own name, under Indian rules for unapproved medicines. Please keep these ready:

  • A prescription from the treating medical oncologist, stating the dose and the partner treatment
  • The pathology or biopsy report showing HER2-positive breast cancer, plus recent scans and a summary of earlier treatment
  • Government-issued photo ID of the patient

How is the order confirmed?

We confirm an order only after the prescription has been checked and, where it applies, the import permit has been issued.

Is Pyrotinib available in India?

No. It is not approved by CDSCO and is not stocked in Indian chemists. CDSCO's expert committee has allowed a phase 3 study in India, but a trial permission is not a marketing licence. It is also not approved by the US FDA, and we found no European approval.

A treating doctor can still request it for one named patient through the Named Patient Program. Another oral HER2 tablet we arrange on the same import basis is Nerlynx.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are stored and shipped as directed on the Chinese pack, in sealed original packaging. Since treatment is taken daily for months, we can plan supply in monthly lots so there is no gap between packs. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Patients across India can receive this oral HER2 medicine through a regulated import route, delivered to their home or treating hospital against a valid oncologist's prescription.

Delhi

Breast cancer clinics in the capital can send the prescription and HER2 report to our New Delhi team, which handles dispatch locally.

Mumbai

Supplies reach oncology departments and patients' homes across Mumbai once the import papers are cleared.

Bangalore

Oncologists here can request the tablets for a named patient and see the written quote before ordering.

Chennai

Patients being treated at Chennai's large cancer hospitals can receive monthly packs without a break in therapy.

Hyderabad

We match the delivery date to the start of each capecitabine cycle so both medicines are on hand together.

Kolkata

Families in Kolkata and the north-east are kept informed at each step, from permit to doorstep.

Pune

Women on long-term oral treatment in Pune can arrange repeat supply from one prescription renewal to the next.

Ahmedabad

The oncologist only needs to share the prescription, pathology report and treatment summary for us to begin.

Vellore

Patients under care at Vellore's teaching hospitals can have each lot delivered to the hospital pharmacy.

Chandigarh

Covers patients travelling from Punjab, Haryana, Himachal and Jammu for breast cancer care.

Lucknow

We coordinate delivery to cancer centres across Uttar Pradesh, both government and private.

Kochi

Patients across Kerala can collect the medicine in Kochi or have it sent to their treating hospital.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 18 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP